Search research articles
Contact Us
Filters
Showing results (51-60 of 120) with videos related to
Page
of 12
Sort By:
Investigational New Drugs
|
February 26, 2014
A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer
Alan L Ho, Brynna L Lipson, Eric J Sherman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2024
Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma
Antoine Desilets, Joris L Vos, Nora Katabi, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
October 17, 2025
Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC
Gabriel Raab, Bin Xu, Anas Alabkaa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2023
Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Laura Boucai, Mahesh Saqcena, Fengshen Kuo, et al.
Oral Oncology
|
September 3, 2025
A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Lara A Dunn, Alan L Ho, Loren S Michel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 29, 2023
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Glenn J Hanna, Myung-Ju Ahn, Jameel Muzaffar, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 4, 2019
A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma
Lara A Dunn, Nadeem Riaz, Matthew G Fury, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 4, 2025
Response to Letter to the Editor from Zhang et al.: Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer
Bhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 12, 2024
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer
Bhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
Cancer
|
June 20, 2020
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer
Glenn J Hanna, Jeffrey P Guenette, Nicole G Chau, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 120) with videos related to
Sort By:
Page
of 12
Investigational New Drugs
|
February 26, 2014
A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer
Alan L Ho, Brynna L Lipson, Eric J Sherman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2024
Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma
Antoine Desilets, Joris L Vos, Nora Katabi, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|
October 17, 2025
Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC
Gabriel Raab, Bin Xu, Anas Alabkaa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2023
Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Laura Boucai, Mahesh Saqcena, Fengshen Kuo, et al.
Oral Oncology
|
September 3, 2025
A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Lara A Dunn, Alan L Ho, Loren S Michel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 29, 2023
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Glenn J Hanna, Myung-Ju Ahn, Jameel Muzaffar, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 4, 2019
A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma
Lara A Dunn, Nadeem Riaz, Matthew G Fury, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 4, 2025
Response to Letter to the Editor from Zhang et al.: Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer
Bhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 12, 2024
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer
Bhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
Cancer
|
June 20, 2020
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer
Glenn J Hanna, Jeffrey P Guenette, Nicole G Chau, et al.
Page
of 12